PLEASANTON, Calif., Oct. 5, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 9, 2023. The event will begin at 9:00 a.m. PT and will conclude at approximately 11:00 a.m. PT.
Veeva will broadcast the presentations live on the company's investor relations website, ir.veeva.com, where a link to the archived webcast will also be available after the event.
Event: | Veeva Systems Virtual Investor Day |
Date: | Thursday, November 9, 2023 |
Time: | 9:00 a.m. PT (12:00 p.m. ET) |
Online event registration can be found on the company's investor relations website or directly at this | |
Webcast: |
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact: | Media Contact: |
Gunnar Hansen | Maria Scurry |

| Last Trade: | US$217.05 |
| Daily Change: | 1.58 0.73 |
| Daily Volume: | 1,582,051 |
| Market Cap: | US$35.680B |
December 04, 2025 December 03, 2025 November 24, 2025 November 20, 2025 November 04, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load